Hofseth BioCare ASA (HBC.OL)
NOK 2.1
(0.95%)
NOK 2.1
(0.95%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.27 NOK | 27.03% |
| 2022 | -0.37 NOK | -5.71% |
| 2021 | -0.35 NOK | -12.9% |
| 2020 | -0.31 NOK | -6.9% |
| 2019 | -0.29 NOK | 12.12% |
| 2018 | -0.33 NOK | -369.42% |
| 2017 | -0.07 NOK | 93.04% |
| 2016 | -1.01 NOK | -6.32% |
| 2015 | -0.95 NOK | -30.14% |
| 2014 | -0.73 NOK | -1.39% |
| 2013 | -0.72 NOK | 44.19% |
| 2012 | -1.29 NOK | -186.67% |
| 2011 | -0.45 NOK | -36.36% |
| 2010 | -0.33 NOK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.04 NOK | 39.6% |
| 2024 Q1 | -0.07 NOK | 45.62% |
| 2023 Q2 | 0.01 NOK | 115.24% |
| 2023 Q4 | -0.13 NOK | -126.09% |
| 2023 Q3 | -0.06 NOK | -493.84% |
| 2023 FY | - NOK | 27.03% |
| 2023 Q1 | -0.10 NOK | 1.14% |
| 2022 Q4 | -0.10 NOK | -7.19% |
| 2022 Q3 | -0.09 NOK | -14.0% |
| 2022 Q2 | -0.08 NOK | 20.46% |
| 2022 FY | - NOK | -5.71% |
| 2022 Q1 | -0.10 NOK | 9.36% |
| 2021 Q2 | -0.07 NOK | 8.13% |
| 2021 Q1 | -0.08 NOK | 19.44% |
| 2021 Q3 | -0.11 NOK | -59.65% |
| 2021 Q4 | -0.11 NOK | 0.0% |
| 2021 FY | - NOK | -12.9% |
| 2020 FY | - NOK | -6.9% |
| 2020 Q1 | -0.05 NOK | 50.36% |
| 2020 Q3 | -0.10 NOK | -62.01% |
| 2020 Q2 | -0.06 NOK | -12.82% |
| 2020 Q4 | -0.09 NOK | 6.71% |
| 2019 Q4 | -0.11 NOK | -86.76% |
| 2019 Q2 | -0.06 NOK | 18.34% |
| 2019 Q1 | -0.07 NOK | 22.96% |
| 2019 Q3 | -0.06 NOK | -3.33% |
| 2019 FY | - NOK | 12.12% |
| 2018 Q2 | -0.08 NOK | 15.01% |
| 2018 FY | - NOK | -369.42% |
| 2018 Q1 | -0.09 NOK | -72.0% |
| 2018 Q4 | -0.09 NOK | -20.8% |
| 2018 Q3 | -0.08 NOK | 6.72% |
| 2017 Q3 | -0.05 NOK | 37.74% |
| 2017 FY | - NOK | 93.04% |
| 2017 Q4 | -0.06 NOK | -7.21% |
| 2017 Q1 | 0.12 NOK | 0.0% |
| 2017 Q2 | -0.08 NOK | -168.67% |
| 2016 Q4 | - NOK | 100.0% |
| 2016 FY | - NOK | -6.32% |
| 2016 Q2 | -0.43 NOK | -72.0% |
| 2016 Q1 | -0.25 NOK | 37.5% |
| 2016 Q3 | -0.36 NOK | 16.28% |
| 2015 Q3 | -0.16 NOK | 30.43% |
| 2015 Q4 | -0.40 NOK | -150.0% |
| 2015 FY | - NOK | -30.14% |
| 2015 Q1 | -0.19 NOK | 0.0% |
| 2015 Q2 | -0.23 NOK | -21.05% |
| 2014 FY | - NOK | -1.39% |
| 2014 Q4 | - NOK | 100.0% |
| 2014 Q3 | -0.16 NOK | 0.0% |
| 2014 Q2 | -0.16 NOK | 5.88% |
| 2014 Q1 | -0.17 NOK | -41.67% |
| 2013 Q1 | -0.28 NOK | 64.56% |
| 2013 Q2 | -0.22 NOK | 21.43% |
| 2013 Q3 | -0.11 NOK | 50.0% |
| 2013 Q4 | -0.12 NOK | -9.09% |
| 2013 FY | - NOK | 44.19% |
| 2012 Q1 | -0.24 NOK | 0.0% |
| 2012 Q3 | -0.12 NOK | 29.41% |
| 2012 Q4 | -0.79 NOK | -558.33% |
| 2012 FY | - NOK | -186.67% |
| 2012 Q2 | -0.17 NOK | 29.17% |
| 2011 Q1 | -0.09 NOK | 0.0% |
| 2011 Q4 | - NOK | 100.0% |
| 2011 FY | - NOK | -36.36% |
| 2011 Q3 | -0.09 NOK | -2.42% |
| 2011 Q2 | -0.09 NOK | -1.64% |
| 2010 Q4 | - NOK | 100.0% |
| 2010 FY | - NOK | 0.0% |
| 2010 Q3 | -0.03 NOK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arctic Bioscience AS | -1.79 NOK | 84.916% |
| Aqua Bio Technology ASA | -0.99 NOK | 72.727% |
| ArcticZymes Technologies ASA | 0.38 NOK | 171.053% |
| BerGenBio ASA | -13.30 NOK | 97.97% |
| PCI Biotech Holding ASA | -0.54 NOK | 50.0% |
| Thor Medical ASA | -0.03 NOK | -749.057% |
| Ultimovacs ASA | -5.50 NOK | 95.091% |